B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Daoussis, Dimitrios ^a   Tsamandas, Athanassios C ^a   Liossis, Stamatis Nick C ^a   Antonopoulos, Ioannis ^a   Karatza, Elli ^a   Yiannopoulos, Georgios ^a   Andonopoulos, Andrew P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYCLOPHOSPHAMIDE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DERMIS; HUMAN; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKIN BIOPSY; SKIN FIBROSIS; SPINDLE CELL; SYSTEMIC SCLEROSIS; ADULT; B LYMPHOCYTE; BIOSYNTHESIS; CLINICAL TRIAL; DIFFUSE SCLERODERMA; DRUG EFFECT; FEMALE; FIBROSIS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SKIN;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; FEMALE; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SCLERODERMA, DIFFUSE; SKIN;

EID: 84862190770     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3879     Document Type: Article

References (30)

1. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010, 49:271-280.
2. Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B, Sica G, Ferraccioli G. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010, 12:R54. 10.1186/ar2965, 2888203, 20338043.
3. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009, 60:578-583. 10.1002/art.24249, 2637937, 19180481.
4. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010, 69:193-197. 10.1136/ard.2008.095463, 19103636.
5. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966. 10.2353/ajpath.2006.060205, 1698806, 16936269.
6. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462. 150999, 12045259.
7. Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H, Tamaki K, Tedder TF, Sato S. B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004, 165:641-650. 10.1016/S0002-9440(10)63328-7, 1618564, 15277237.
8. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008, 172:1650-1663. 10.2353/ajpath.2008.071049, 2408424, 18467694.
9. Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, Sato S. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008, 58:3574-3584. 10.1002/art.23995, 18975313.
10. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004, 15:255-273. 10.1016/j.cytogfr.2004.03.006, 15207816.
11. Yi ES, Lee H, Yin S, Piguet P, Sarosi I, Kaufmann S, Tarpley J, Wang NS, Ulich TR. Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. Am J Pathol 1996, 149:539-548. 1865324, 8701993.
12. Hoyle GW, Li J, Finkelstein JB, Eisenberg T, Liu JY, Lasky JA, Athas G, Morris GF, Brody AR. Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor. Am J Pathol 1999, 154:1763-1775. 10.1016/S0002-9440(10)65432-6, 1866633, 10362801.
13. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676. 10.1056/NEJMoa052955, 16790699.
14. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
15. Daoussis D, Liossis SN, Tsamandas A, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP. Effect of long term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2011,
16. Tsamandas AC, Thomopoulos K, Zolota V, Kourelis T, Karatzas T, Ravazoula P, Tepetes K, Petsas T, Karavias D, Karatza C, Bonikos DS, Gogos C. Potential role of bcl-2 and bax mRNA and protein expression in chronic hepatitis type B and C: a clinicopathologic study. Mod Pathol 2003, 16:1273-1288. 10.1097/01.MP.0000097367.56816.5E, 14681329.
17. Vis AN, Kranse R, Nigg AL, van der Kwast TH. Quantitative analysis of the decay of immunoreactivity in stored prostate needle biopsy sections. Am J Clin Pathol 2000, 113:369-373. 10.1309/CQWY-E3F6-9KDN-YV36, 10705817.
18. Hatanaka Y, Hashizume K, Kamihara Y, Itoh H, Tsuda H, Osamura RY, Tani Y. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest™ in breast carcinoma by image analysis. Pathol Int 2001, 51:33-36. 10.1046/j.1440-1827.2001.01162.x, 11148461.
19. Olson LE, Soriano P. Increased PDGFRα activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell 2009, 16:303-313. 10.1016/j.devcel.2008.12.003, 2664622, 19217431.
20. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE, Huber PE. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005, 201:925-935. 10.1084/jem.20041393, 2213091, 15781583.
21. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007, 29:976-985. 10.1183/09031936.00152106, 17301095.
22. Rice AB, Moomaw CR, Morgan DL, Bonner JC. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 1999, 155:213-221. 10.1016/S0002-9440(10)65115-2, 1866660, 10393853.
23. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009, 60:219-224. 10.1002/art.24186, 19116940.
24. Gay S, Jones RE, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989, 92:301-303. 10.1111/1523-1747.ep12276895, 2918236.
25. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, Leroy EC, Sutherland S, Silver RM. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995, 22:1876-1883.
26. Pandolfi A, Florita M, Altomare G, Pigatto P, Donati MB, Poggi A. Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis. Proc Soc Exp Biol Med 1989, 191:1-4.
27. Klareskog L, Gustafsson R, Scheynius A, Hallgren R. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990, 33:1534-1541. 10.1002/art.1780331011, 2171541.
28. Zheng XY, Zhang JZ, Tu P, Ma SQ. Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci 1998, 18:90-97. 10.1016/S0923-1811(98)00027-9, 9833975.
29. Soria A, Cario-Andre M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taieb A. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 2008, 216:109-117. 10.1159/000111507, 18216472.
30. Jordan S, Distler J, Maourer B, Allanore Y, van Laar J, Distler O. Safety and efficacy of Rituximab in SSC: an analysis from the European Trial and Research Group. Proceedings of the 2nd Systemic Sclerosis World Congress; February 2-4 2012; Madrid, Spain 2012, 51(Supplement 2):ii25. Rheumatology, UK.